Literature DB >> 30059790

Small airway function in children with mild to moderate asthmatic symptoms.

Hanna Knihtilä1, Anne Kotaniemi-Syrjänen2, Anna S Pelkonen2, Mika J Mäkelä2, L Pekka Malmberg2.   

Abstract

BACKGROUND: Clinical significance of small airway obstruction in mild pediatric asthma is unclear.
OBJECTIVE: To evaluate small airway properties in children with mild to moderate asthmatic symptoms and the association of small airway function with asthma control and exercise-induced bronchoconstriction (EIB).
METHODS: Children (5-10 years old) with recurrent wheezing (n = 42) or persistent troublesome cough (n = 16) and healthy controls (n = 19) performed impulse oscillometry (IOS), spirometry, and a multiple-breath nitrogen washout (MBNW) test. Exhaled nitric oxide (NO) was measured at multiple flow rates to determine alveolar NO concentration (Calv). Asthma control was evaluated with the Childhood Asthma Control Test (C-ACT), short-acting β2-agonist (SABA) use within the past month, and asthma exacerbations within the past year.
RESULTS: IOS, spirometry, and exhaled NO indexes that are related to small airway function differed between children with recurrent wheezing and healthy controls, whereas only forced expiratory flow at 25% to 75% of the forced vital capacity was associated with persistent cough. The MBNW indexes showed no difference between the groups. Among symptomatic children, conducting airway ventilation inhomogeneity and Calv were associated with asthma exacerbations (P = .03 and P = .002, respectively), and lung clearance index and Calv were associated with EIB (P = .04 and P = .004, respectively). None of the proposed small airway indexes was associated with the C-ACT score or SABA use.
CONCLUSION: Subtle changes were observed in the proposed small airway indexes of IOS, spirometry, and exhaled NO among children with mild to moderate recurrent wheezing. Small airway dysfunction, expressed as ventilation inhomogeneity indexes and Calv, was also associated with asthma exacerbations and EIB.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30059790     DOI: 10.1016/j.anai.2018.07.026

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

Review 1.  Small Airway Disease in Pediatric Asthma: the Who, What, When, Where, Why, and How to Remediate. A Review and Commentary.

Authors:  Russell J Hopp; Mark C Wilson; M Asghar Pasha
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-26       Impact factor: 8.667

2.  MMEF25-75 may predict significant BDR and future risk of exacerbations in asthmatic children with normal baseline FEV1.

Authors:  Snezhina Lazova; Stamatios Priftis; Guergana Petrova; Emilia Naseva; Tsvetelina Velikova
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-02-15

3.  The predictive role of small airway dysfunction and airway inflammation biomarkers for asthma in preschool and school-age children: a study protocol for a prospective cohort study.

Authors:  Qinyuan Li; Qi Zhou; Yuanyuan Li; Enmei Liu; Zhou Fu; Jian Luo; Sha Liu; Fangjun Liu; Yaolong Chen; Zhengxiu Luo
Journal:  Transl Pediatr       Date:  2021-10

4.  Peripheral airways involvement in children with asthma exacerbation.

Authors:  Maria Wawszczak; Marek Kulus; Joanna Peradzyńska
Journal:  Clin Respir J       Date:  2021-10-29       Impact factor: 1.761

5.  Impact of community respiratory viral infections in urban children with asthma.

Authors:  Toby C Lewis; Ediri E Metitiri; Graciela B Mentz; Xiaodan Ren; Adam M Goldsmith; Breanna N Eder; Kyra E Wicklund; Megan P Walsh; Adam T Comstock; Jeannette M Ricci; Sean R Brennan; Ginger L Washington; Kendall B Owens; Bhramar Mukherjee; Thomas G Robins; Stuart A Batterman; Marc B Hershenson
Journal:  Ann Allergy Asthma Immunol       Date:  2018-10-29       Impact factor: 6.347

6.  Ventilation heterogeneity in children with severe asthma.

Authors:  Amy G Nuttall; Caroline S Beardsmore; Erol A Gaillard
Journal:  Eur J Pediatr       Date:  2021-05-13       Impact factor: 3.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.